
G Caleb Alexander

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5087339/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. Annual Review of Public Health, 2015, 36, 559-574.	17.4	1,138
2	Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US. JAMA Network Open, 2020, 3, e2021476.	5.9	332
3	An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. Annals of Internal Medicine, 2020, 173, 57-58.	3.9	278
4	Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000–2010. Medical Care, 2013, 51, 870-878.	2.4	268
5	Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. JAMA Internal Medicine, 2015, 175, 1642.	5.1	207
6	Evaluation of Aducanumab for Alzheimer Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1717.	7.4	152
7	Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. American Journal of Emergency Medicine, 2014, 32, 421-431.	1.6	128
8	Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Internal Medicine, 2018, 178, 1190.	5.1	120
9	Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012. Diabetes Care, 2014, 37, 985-992.	8.6	119
10	Most Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To Access. Health Affairs, 2015, 34, 484-492.	5.2	107
11	Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. American Journal of Medicine, 2017, 130, 293-305.	1.5	96
12	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatology, The, 2022, 4, e33-e41.	3.9	96
13	Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis. Drug and Alcohol Dependence, 2016, 165, 1-8.	3.2	95
14	Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diabetes and Endocrinology,the, 2016, 4, 943-956.	11.4	92
15	Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10ÂUS States. Addiction, 2017, 112, 1784-1796.	3.3	91
16	The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms. Epidemiologic Reviews, 2020, 42, 154-166.	3.5	81
17	Rethinking Opioid Prescribing to Protect Patient Safety and Public Health. JAMA - Journal of the American Medical Association, 2012, 308, 1865.	7.4	79
18	Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Medicine, 2018, 16, 69.	5.5	77

#	Article	IF	CITATIONS
19	Promotion of Prescription Drugs to Consumers and Providers, 2001–2010. PLoS ONE, 2013, 8, e55504.	2.5	71
20	Effect of a "pill mill―law on opioid prescribing and utilization: The case of Texas. Drug and Alcohol Dependence, 2016, 159, 190-197.	3.2	71
21	Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology, 2021, 7, 412.	7.1	63
22	Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Annals of the Rheumatic Diseases, 2020, 79, 285-291.	0.9	61
23	Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0234065.	2.5	59
24	Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP). Addiction, 2017, 112, 311-319.	3.3	53
25	Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics. Annals of Internal Medicine, 2016, 165, 565.	3.9	52
26	Association Between Chronic Use of Immunosuppresive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System. Clinical Infectious Diseases, 2021, 73, e4124-e4130.	5.8	51
27	Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study. Clinical Infectious Diseases, 2022, 75, e516-e524.	5.8	44
28	Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. American Journal on Addictions, 2015, 24, 24-29.	1.4	43
29	Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. BMJ Open, 2020, 10, e039978.	1.9	42
30	Quality of Prescribing by Physicians, Nurse Practitioners, and Physician Assistants in the United States. Pharmacotherapy, 2018, 38, 417-427.	2.6	41
31	Prescription drug monitoring program design and function: A qualitative analysis. Drug and Alcohol Dependence, 2017, 180, 395-400.	3.2	40
32	Moving Addiction Care to the Mainstream — Improving the Quality of Buprenorphine Treatment. New England Journal of Medicine, 2018, 379, 4-6.	27.0	40
33	National Trends in Use of Sodiumâ€Glucose Cotransporterâ€2 Inhibitors and Glucagonâ€like Peptideâ€1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020. Journal of the American Heart Association, 2022, 11, e023811.	3.7	40
34	Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Mayo Clinic Proceedings, 2019, 94, 2220-2229.	3.0	39
35	Changes in Short-term, Long-term, and Preventive Care Delivery in US Office-Based and Telemedicine Visits During the COVID-19 Pandemic. JAMA Health Forum, 2021, 2, e211529.	2.2	35
36	The Problem of Aducanumab for the Treatment of Alzheimer Disease. Annals of Internal Medicine, 2021, 174, 1303-1304.	3.9	35

#	Article	IF	CITATIONS
37	Impact of abuseâ€deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiology and Drug Safety, 2015, 24, 197-204.	1.9	34
38	More States Should Regulate Pain Management Clinics to Promote Public Health. American Journal of Public Health, 2017, 107, 240-243.	2.7	31
39	Recommendations to Limit Life Support. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 633-639.	5.6	30
40	Primary Care Physicians' Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion. Clinical Journal of Pain, 2016, 32, 279-284.	1.9	30
41	Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLoS ONE, 2018, 13, e0195012.	2.5	30
42	Impact of Florida's prescription drug monitoring program and pill mill law on highâ€ r isk patients: A comparative interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2018, 27, 422-429.	1.9	29
43	ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2020, 77, 84-112.	1.0	29
44	Association Between Pharmacy Closures and Adherence to Cardiovascular Medications Among Older US Adults. JAMA Network Open, 2019, 2, e192606.	5.9	27
45	Prescription Drug Abuse. JAMA Internal Medicine, 2015, 175, 302.	5.1	26
46	Protocol: mixed-methods study to evaluate implementation, enforcement, and outcomes of U.S. state laws intended to curb high-risk opioid prescribing. Implementation Science, 2018, 13, 37.	6.9	25
47	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. JAMA Network Open, 2020, 3, e2023677.	5.9	24
48	Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States. Annals of Internal Medicine, 2021, 174, 1395-1403.	3.9	24
49	Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States. Annals of Internal Medicine, 2021, 174, 428-430.	3.9	23
50	Effects of State Opioid Prescribing Laws on Use of Opioid and Other Pain Treatments Among Commercially Insured U.S. Adults. Annals of Internal Medicine, 2022, 175, 617-627.	3.9	23
51	Nonâ€buprenorphine opioid utilization among patients using buprenorphine. Addiction, 2017, 112, 1045-1053.	3.3	22
52	Relationship between highâ€risk patients receiving prescription opioids and highâ€volume opioid prescribers. Addiction, 2018, 113, 677-686.	3.3	22
53	Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1886-1888.	4.5	21
54	Implementation and enforcement of state opioid prescribing laws. Drug and Alcohol Dependence, 2020, 213, 108107.	3.2	21

#	Article	IF	CITATIONS
55	Impact of a drug utilization review program on highâ€risk use of prescription controlled substances. Pharmacoepidemiology and Drug Safety, 2014, 23, 419-427.	1.9	20
56	Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey. Drug and Alcohol Dependence, 2021, 225, 108811.	3.2	20
57	Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study. Pharmacotherapy, 2017, 37, 12-24.	2.6	18
58	National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012. PLoS ONE, 2015, 10, e0119292.	2.5	16
59	Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. JAMA Network Open, 2021, 4, e2128782.	5.9	16
60	Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics. Clinical Therapeutics, 2018, 40, 95-102.e2.	2.5	14
61	Effects of Prescription Drug Insurance on Hospitalization and Mortality: Evidence from Medicare Part D. Journal of Risk and Insurance, 2019, 86, 595-628.	1.6	13
62	Cardiovascular safety signals with dipeptidyl peptidaseâ€4 inhibitors: <scp>A</scp> disproportionality analysis among highâ€risk patients. Pharmacoepidemiology and Drug Safety, 2018, 27, 660-667.	1.9	12
63	Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis. Journal of the National Cancer Institute, 2022, 114, 191-202.	6.3	12
64	Reducing Branded Prescription Drug Prices: A Review of Policy Options. Pharmacotherapy, 2017, 37, 1469-1478.	2.6	10
65	Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure. Mayo Clinic Proceedings, 2020, 95, 2408-2419.	3.0	10
66	Ambulatory <scp>noninsulin</scp> treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 1843-1850.	4.4	9
67	Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. Addiction, 2022, 117, 969-976.	3.3	7
68	How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. Journal of Oncology Practice, 2015, 11, 313-318.	2.5	5
69	Predictors of new persistent opioid use after benign hysterectomy in the United States. American Journal of Obstetrics and Gynecology, 2022, 227, 68.e1-68.e24.	1.3	5
70	Rejection of Aducanumab (Aduhelm) by the Health Care Community. Medical Care, 2022, 60, 392-393.	2.4	5
71	Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients. Drug Safety, 2016, 39, 375-380.	3.2	3
72	Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open, 2021, 7, e001399.	3.8	3

#	Article	IF	CITATIONS
73	More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review. Journal of Clinical Epidemiology, 2021, 137, 113-125.	5.0	3
74	The Opioid Industry Documents Archive: A Living Digital Repository. American Journal of Public Health, 2022, 112, 1126-1129.	2.7	3
75	Cardiovascular risks associated with clarithromycin. BMJ, The, 2016, 352, i23.	6.0	2
76	Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. PLoS ONE, 2019, 14, e0225109.	2.5	2
77	Is Treatment Heterogeneity an <scp>A</scp> chilles' Heel for Comparative Effectiveness Research?. Pharmacotherapy, 2012, 32, 583-585.	2.6	1
78	Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. American Journal on Addictions, 2014, 24, n/a-n/a.	1.4	1
79	Capsule Commentary on Faerber et al., Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs. Journal of General Internal Medicine, 2014, 29, 180-180.	2.6	0
80	The United States Postal Service: an Essential Public Health Agency?. Journal of General Internal Medicine, 2020, 35, 3699-3701.	2.6	0
81	Thromboprophylaxis in people hospitalized with <scp>COVID</scp> â€19: Assessing intermediate or standard doses in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis. 2022. 6	2.3	ο